JP2025504379A5 - - Google Patents
Info
- Publication number
- JP2025504379A5 JP2025504379A5 JP2024540912A JP2024540912A JP2025504379A5 JP 2025504379 A5 JP2025504379 A5 JP 2025504379A5 JP 2024540912 A JP2024540912 A JP 2024540912A JP 2024540912 A JP2024540912 A JP 2024540912A JP 2025504379 A5 JP2025504379 A5 JP 2025504379A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- cancer
- compound according
- pharmaceutically acceptable
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263296676P | 2022-01-05 | 2022-01-05 | |
| US63/296,676 | 2022-01-05 | ||
| PCT/US2023/010204 WO2023133201A1 (en) | 2022-01-05 | 2023-01-05 | Deuterium-enriched piperidinyl-methyl-purine amines and related compounds and their use in treating diseases and conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025504379A JP2025504379A (ja) | 2025-02-12 |
| JP2025504379A5 true JP2025504379A5 (enExample) | 2026-01-14 |
Family
ID=87074217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024540912A Pending JP2025504379A (ja) | 2022-01-05 | 2023-01-05 | 重水素濃縮ピペリジニル－メチル－プリンアミン及び関連化合物、ならびに疾患及び状態の治療におけるそれらの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12492203B2 (enExample) |
| EP (1) | EP4460502A4 (enExample) |
| JP (1) | JP2025504379A (enExample) |
| KR (1) | KR20240158230A (enExample) |
| CN (1) | CN119032094A (enExample) |
| AU (1) | AU2023205553A1 (enExample) |
| CA (1) | CA3242612A1 (enExample) |
| IL (1) | IL314062A (enExample) |
| MX (1) | MX2024008450A (enExample) |
| WO (1) | WO2023133201A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021026803A1 (en) | 2019-08-14 | 2021-02-18 | Novartis Ag | Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents |
| KR20250129690A (ko) * | 2022-12-12 | 2025-08-29 | 케이36 테라퓨틱스, 인크. | 피페리딘일-메틸-푸린 아민을 함유하는 약학적 조성물과 질환 및 병태 치료에서 이의 용도 |
| WO2025106786A1 (en) * | 2023-11-17 | 2025-05-22 | K36 Therapeutics, Inc. | Deuterium-enriched piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions |
| CN117843641B (zh) * | 2023-12-28 | 2025-04-25 | 和径医药科技（上海）有限公司 | Nsd3抑制剂及其制备方法和应用 |
| WO2025259850A1 (en) * | 2024-06-12 | 2025-12-18 | K36 Therapeutics, Inc. | Pharmaceutical compositions containing a deuterium-enriched piperidinyl-methyl-purine amine and their use in treating diseases and conditions |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2972242A1 (en) | 2008-09-18 | 2010-04-22 | Auspex Pharmaceuticals, Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| EP2463289A1 (en) * | 2010-11-26 | 2012-06-13 | Almirall, S.A. | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors |
| WO2021026803A1 (en) * | 2019-08-14 | 2021-02-18 | Novartis Ag | Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents |
| DK4013756T3 (da) | 2019-09-20 | 2024-05-27 | Novartis Ag | MLL1-inhibitorer og anticancermidler |
| TW202200589A (zh) | 2020-05-28 | 2022-01-01 | 瑞士商諾華公司 | Ｍｌｌ１抑制劑及抗癌劑 |
| US20250326752A1 (en) | 2022-05-18 | 2025-10-23 | K36 Therapeutics, Inc. | Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions |
| WO2023225150A1 (en) | 2022-05-18 | 2023-11-23 | K36 Therapeutics, Inc. | Piperidinyl-methyl-purine amine fumaric acid salts, crystalline forms, and their use in treating medical diseases and conditions |
| WO2023225144A1 (en) | 2022-05-18 | 2023-11-23 | K36 Therapeutics, Inc. | Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions |
| AU2023273656A1 (en) | 2022-05-18 | 2024-11-28 | K36 Therapeutics, Inc. | Piperidinyl-methyl-purine amine d-tartaric acid salts, crystalline forms, and their use in treating medical diseases and conditions |
| US20250361235A1 (en) | 2022-05-23 | 2025-11-27 | K36 Therapeutics, Inc. | Piperidinyl-methylpurine benzenes and related compounds and their use in treating diseases and conditions |
| WO2023230038A1 (en) | 2022-05-23 | 2023-11-30 | K36 Therapeutics, Inc. | Piperidinyl-methylpurine pyrimidines and related compounds and their use in treating diseases and conditions |
| EP4583915A1 (en) | 2022-09-09 | 2025-07-16 | The Trustees Of Columbia University In The City Of New York | Methods of treating neuroendocrine prostate cancer (nepc) by inhibiting nuclear receptor binding set domain protein 2 (nsd2) |
| KR20250129690A (ko) | 2022-12-12 | 2025-08-29 | 케이36 테라퓨틱스, 인크. | 피페리딘일-메틸-푸린 아민을 함유하는 약학적 조성물과 질환 및 병태 치료에서 이의 용도 |
| WO2025106786A1 (en) | 2023-11-17 | 2025-05-22 | K36 Therapeutics, Inc. | Deuterium-enriched piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions |
-
2023
- 2023-01-05 JP JP2024540912A patent/JP2025504379A/ja active Pending
- 2023-01-05 AU AU2023205553A patent/AU2023205553A1/en active Pending
- 2023-01-05 CA CA3242612A patent/CA3242612A1/en active Pending
- 2023-01-05 WO PCT/US2023/010204 patent/WO2023133201A1/en not_active Ceased
- 2023-01-05 EP EP23737585.2A patent/EP4460502A4/en active Pending
- 2023-01-05 KR KR1020247026101A patent/KR20240158230A/ko active Pending
- 2023-01-05 CN CN202380022643.3A patent/CN119032094A/zh active Pending
- 2023-01-05 IL IL314062A patent/IL314062A/en unknown
-
2024
- 2024-06-28 US US18/758,953 patent/US12492203B2/en active Active
- 2024-07-04 MX MX2024008450A patent/MX2024008450A/es unknown
-
2025
- 2025-10-24 US US19/368,828 patent/US20260049083A1/en active Pending